Director Grant C. Bogle filed an initial statement of beneficial ownership with the SEC on November 9, 2026, disclosing no securities held in Immuneering Corp (NASDAQ:IMRX).

Key Highlights

  • Reporting person: Grant C. Bogle, identified as a Director of Immuneering Corp.
  • Date of event: The event requiring the statement occurred on 11/09/2026, per the filing.
  • No securities held: The filing states, "No securities are beneficially owned," covering both non-derivative and derivative securities.
  • Filing type: This is an initial statement, not an amendment to a prior filing.
  • Signed by attorney-in-fact: The form was signed by Michael D. Bookman as Attorney-in-Fact for Grant C. Bogle on 11/09/2026.

Bogle's Initial Beneficial Ownership Report Shows No Holdings in Immuneering Corp

According to the filing, Grant C. Bogle submitted an initial statement of beneficial ownership in connection with his role as a Director of Immuneering Corp, listed on NASDAQ under the symbol IMRX. The statement was filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, which requires officers, directors, and certain shareholders to disclose their holdings upon assuming a reportable status with a public company.

The filing covers both Table I, addressing non-derivative securities such as common stock, and Table II, addressing derivative securities such as options, warrants, and convertible instruments. In both tables, the registrant reported no entries. The filing explicitly notes in its remarks section: "No securities are beneficially owned." Neither direct nor indirect ownership of any class of security was reported.

The form was executed by Michael D. Bookman, identified as Attorney-in-Fact for Grant C. Bogle, and bears a signature date of 11/09/2026, the same date as the event requiring the statement. Bogle's listed address is care of Immuneering Corporation, 245 Main Street, Second Floor, Cambridge, Massachusetts 02142.

What Was Disclosed

Grant C. Bogle, a newly reportable Director at Immuneering Corp (NASDAQ:IMRX), filed an initial beneficial ownership statement dated 11/09/2026 disclosing zero holdings in both non-derivative and derivative securities of the company.